Option chain shows key data for Full Alliance Group's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Full Alliance Group.

Full Alliance Group (OTC:FAGI) Stock, Option Chain

Full Alliance Group Inc provides nutraceutical and supplement products; extracorporeal blood oxygenation and ozonation treatments for patients. The company derives revenues from merchandise sales from physical locations and online channels.

FULL ALLIANCE GROUP INC by Full Alliance Group, Inc.

Full Alliance Group Inc

VinFast Auto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFS#NASDAQ">VFS</a>) reported quarterly losses of $(0.23) per share which met the analyst consensus estimate. This is a 14.81 percent increase over losses of $(0.27) per share from the same period last year. The company reported quarterly sales of $512.00 million which missed the analyst consensus estimate of $732.16 million by 30.07 percent. This is a 49.42 percent increase over sales of $342.66 million the same period last year.

Earnings

News

VinFast Auto Q3 EPS $(0.23), Inline, Sales $512.00M Miss $732.16M Estimate

American astrophysicist Neil deGrasse Tyson <a href="https://www.benzinga.com/news/24/10/41546631/neil-degrasse-tyson-calls-elon-musks-mars-mission-a-space-frontier-days-after-his-comments-on-spacex">dismissed</a> SpaceX CEO Elon Musk&#8216;s ambitions to send people to Mars, saying that unless there is a push caused by a shift in geopolitics, it will not be possible as a pure exploration project.
What Happened: &#8220;I have strong views on that. My read of the history of space exploration is such that we do big, expensive things only when it&#8217;s geopolitically expedient, such as we feel threatened by an enemy,&#8221; Tyson said in an <a href="https://www.youtube.com/watch?v=WMzgXHhKarY">interview</a> with Bill Maher. 
The trip to Mars won&#8217;t happen because Musk believes it&#8217;s the next big thing to do, Tyson said, while adding that it would be difficult to gain investment for the Starship project given its high costs and low return on investment. 
&#8220;For him to just say, let&#8217;s go to Mars because it&#8217;s the next thing to do. What is that venture capitalist meeting look like? &#8216;So, Elon, what do you want to do?&#8217; &#8216;I want to go to Mars?&#8217; &#8216;How much will it cost?&#8217; &#8216;$1 trillion.&#8217; &#8216;Is it safe?&#8217; &#8216;No. People will probably die.&#8217; &#8216;What&#8217;s the return on the investment?&#8217; &#8216;Nothing.&#8217; That&#8217;s a five-minute meeting. And it doesn&#8217;t happen,&#8221; he said.
The U.S. will get people to Mars only if there is a geopolitical push like a memo from China that it is planning to put up a military base on Mars, according to Tyson. In that case, the U.S. will aim to get to Mars in ten months and NASA will get the spacecraft from SpaceX for the purpose, he said. 
&#8220;So I don&#8217;t see it happening until governments judge that it&#8217;s geopolitically in our interest,&#8221; Tyson said. &#8220;I got nothing against Mars.&#8221;
According to Tyson, instead of developing Mars to be liveable once Earth becomes unlivable, it would be better to invest in Earth itself.
Why It Matters: Musk, meanwhile, dismissed Tyson. 
&#8220;Wow, they really don&#8217;t get it. Mars is critical to the long-term survival of consciousness. Also, I&#8217;m not going to ask any venture capitalists for money. I realize that it makes no sense as an investment. That&#8217;s why I&#8217;m gathering resources,&#8221; he wrote.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Wow, they really don't get it. Mars is critical to the long-term survival of consciousness. Also, I'm not going to ask any venture capitalists for money. I realize that it makes no sense as an investment. That's why I'm gathering resources. <a href="https://t.co/XVCpHKlusD">https://t.co/XVCpHKlusD</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1860322925783445956?ref_src=twsrc%5Etfw">November 23, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Musk has previously said that SpaceX&#8217;s satellite internet segment called Starlink will fund his vision to travel to Mars aboard the company&#8217;s Starship launch vehicle.
The Starship launch vehicle is currently in the development and testing phase. The company has conducted six test flights of the vehicle to date but without a payload. 
"…I would not be surprised if we fly 400 Starship launches in the next four years,&#8221; SpaceX President and COO&nbsp;Gwynne Shotwell&nbsp;<a href="https://www.benzinga.com/general/space/24/11/42105704/spacex-ceo-elon-musk-reveals-technical-glitch-that-led-company-to-drop-key-objective-of-starships-6th-test-flight" target="_blank" rel="noreferrer noopener">said at the Baron Investment Conference</a>&nbsp;in New York earlier this month.
SpaceX is a privately held company. Unlike Musk's publicly held EV company Tesla, SpaceX&nbsp;<a href="https://www.benzinga.com/24/11/42022150/spacex-to-launch-tender-offer-valuing-company-at-over-250-billion-report" target="_blank" rel="noreferrer noopener">does not divulge its financials</a>&nbsp;periodically. Shotwell said at the conference that the company will make "some money" on Starlink this year.
"We are going to make some money on Starlink this year. But ultimately I think Starship will be the thing that takes us over the top as one of the most valuable companies," she said.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/space/24/11/42183996/faa-invites-comments-on-increasing-spacexs-starship-launches-by-5x-to-25-next-year">FAA Invites Comments On Increasing SpaceX&#8217;s Starship Launches By 5X To 25 Next Year</a></li>
</ul>
Photos courtesy: Wikimedia and Shutterstock

SPACE

Tech

TSLA

Astrophysicist Neil deGrasse Tyson Dismisses Elon Musk's Mars Vision: SpaceX CEO Hits Back, Says 'They Really Don't Get It'

UBS analyst Thomas Wadewitz assumes JetBlue Airways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) with a Sell rating and announces Price Target of $5.

Price Target

Initiation

Analyst Ratings

JBLU

UBS Assumes JetBlue Airways at Sell, Announces Price Target of $5

<ul>
<li>AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint)</li>
<li>Statistically significant improvement in cognition compared to placebo (p=0.011, NSAQ)</li>
<li>Statistically significant improvement in narcolepsy overall compared to placebo (p=0.024, PGI-C)</li>
<li>Cataplexy response (≥50% improvement) achieved by 72% of patients at 1 month and 82% at 6 months</li>
<li>Improvement in excessive daytime sleepiness (EDS), assessed by the CGI-C, achieved by 84% of patients at 1 month and 78% at 6 months</li>
<li>Improvement in narcolepsy overall, assessed by the CGI-C, achieved by 90% of patients at 1 month and 90% at 6 months</li>
<li>Well-tolerated with long-term safety profile consistent with previously completed trials and no new safety signals detected</li>
<li>NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Axsome The</li>
</ul>

AXSM

Axsome Therapeutics Reveals AXS-12 Meets Primary Endpoint In ENCORE Long-Term Phase 3 Trial In Narcolepsy

UBS analyst Thomas Wadewitz assumes Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) with a Buy rating and announces Price Target of $88.

UBS Assumes Delta Air Lines at Buy, Announces Price Target of $88

Needham analyst Chris Pierce reiterates Blue Bird (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) with a Buy and announces $66 price target.

Reiteration

BLBD

Needham Reiterates Buy on Blue Bird, Announces $66 Price Target

<ul>
<li>MariTide Demonstrated up to ~20% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau in People Living With Obesity or Overweight</li>
<li>MariTide is the First Obesity Treatment With Monthly or Less Frequent Dosing to Demonstrate Safe and Effective Weight Loss in a Phase 2 Study</li>
<li>In People With Type 2 Diabetes Living With Obesity or Overweight MariTide Demonstrated up to ~17% Average Weight Loss Without a Weight Loss Plateau and Lowered Average HbA1c by up to 2.2 Percentage Points at 52 Weeks</li>
<li>MariTide Delivered Substantial Improvements Across Cardiometabolic Parameters</li>
<li>Amgen Announces "MARITIME," a Phase 3 Clinical Development Program in Obesity and Obesity-Related Conditions</li>
</ul>

Biotech

Health Care

General

AMGN

Amgen Announced Data At 52 Weeks In Phase 2 Study With MariTide (Maridebart Cafraglutide, Formerly AMG 133) Subcutaneously Administered Monthly Or Less Frequently, Showing Up To ~20% Average Weight Loss At Week 52 Without A Weight Loss Plateau

UBS analyst Thomas Wadewitz assumes United Airlines Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) with a Buy rating and announces Price Target of $139.

UBS Assumes United Airlines Holdings at Buy, Announces Price Target of $139

Kohl's Sees FY24 EPS Of $1.20-$1.50 (Prior View: $1.75-$2.25); Projects Net Sales Decrease Of (7)%-(8)%

<ul>
<li>- Upon closing, Arrowhead will receive $825 million immediately, including an upfront payment and an equity investment at a 35% premium, and will receive an additional $250 million paid over five years</li>
<li>- Arrowhead has potential to receive an additional $300 million in near-term clinical trial enrollment-related milestone payments and is eligible for future potential milestone payments up to $10 billion and royalties on sales</li>
<li>- Sarepta to receive investigational treatments that leverage Arrowhead's leading Targeted RNAi Molecule platform</li>
</ul>

ARRW

SRPT

Arrowhead Pharmaceuticals And Sarepta Therapeutics Enter Global License And Collaboration Deal For Genetic Disease Programs

Qualcomm Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) <a href="https://www.benzinga.com/news/24/09/40968128/qualcomm-reportedly-eyes-potential-takeover-of-intel-amid-60-stock-decline-but-antitrust-concerns-lo">interest in acquiring</a> Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) is reportedly waning due to the "complexities" involved.
What Happened: The challenges of executing such a deal with Intel have cooled Qualcomm&#8217;s enthusiasm, <a href="https://www.bloomberg.com/news/articles/2024-11-26/qualcomm-s-takeover-interest-in-intel-is-said-to-cool">Bloomberg</a> reported.
In September, reports suggested that&nbsp;Qualcomm approached&nbsp;Intel for a potential takeover, which would have been a significant merger in the tech sector.
Qualcomm might still consider purchasing parts of Intel or revisiting the idea of a full acquisition in the future.
This comes after Qualcomm outlined its strategy last week to diversify its business, aiming to boost annual revenue by $22 billion by 2029. CEO Cristiano Amon stated in an interview that no major acquisition is currently deemed necessary to achieve this target.
Qualcomm and Intel did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment. 
See Also: <a href="https://www.benzinga.com/24/11/42157390/intels-federal-chips-grant-shrinks-below-8b-as-biden-administration-recalibrates-chips-act-funding-report">Intel&#8217;s Federal Chips Grant Shrinks Below $8B As Biden Administration Recalibrates CHIPS Act Funding: Report</a>
Intel, once a leader in the chip industry, has faced setbacks, losing ground in the AI chip market.
In August, Intel&nbsp;announced a <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40168042/intels-10b-cost-cut-seen-as-necessary-but-not-enough-for-competitive-edge-analyst">$10 billion cost-cutting&nbsp;initiative</a>, including workforce reductions and dividend suspension. Analysts have expressed skepticism about the potential deal, citing risks and financial implications for Qualcomm.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: The potential acquisition of Intel by Qualcomm has been a topic of interest since September, when&nbsp;<a href="https://www.benzinga.com/news/24/09/40968128/qualcomm-reportedly-eyes-potential-takeover-of-intel-amid-60-stock-decline-but-antitrust-concerns-lo">Qualcomm reportedly considered the takeover</a>&nbsp;amid Intel&#8217;s 60% stock decline.
However, antitrust concerns have posed significant hurdles. Furthermore,&nbsp;<a href="https://www.benzinga.com/m-a/24/09/40983591/qualcomm-takeover-of-intel-is-logically-unlikely-in-face-of-regulatory-challenges-analyst-says">analysts have expressed doubts</a>&nbsp;about the feasibility of such a merger, citing regulatory challenges.
Adding to Intel&#8217;s challenges, the company is set to <a href="https://www.benzinga.com/24/11/42157390/intels-federal-chips-grant-shrinks-below-8b-as-biden-administration-recalibrates-chips-act-funding-report">receive less than $8 billion</a> in federal CHIPS Act funding, a reduction from the $8.5 billion initially planned. This funding cut comes as Intel struggles to meet its revenue targets with its Gaudi AI chips, as noted by CEO Pat Gelsinger during a third-quarter earnings call. The uptake of these chips has been <a href="https://www.benzinga.com/markets/equities/24/11/41686435/intel-says-it-wont-even-make-500m-from-gaudi-ai-chips-in-2024-despite-nvidia-minting-billions-ce">slower than expected</a>, impacting Intel&#8217;s financial outlook.
Price Action: Qualcomm stock gained 1.3% on Monday to close at $158.82, while Intel's stock rose 1.5% to close at $24.87. Year-to-date, Qualcomm shares are up 13.3%, while Intel's shares are down 48%, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42156373/marc-benioff-warns-were-near-the-upper-limits-of-llms-the-future-of-ai-lies-in-autonomous-agents-not-bots-like-chatgpt?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Marc Benioff Says The Future Of AI Not In Bots Like ChatGPT But In Autonomous Agents</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Markets

Media

INTC

QCOM

Qualcomm's Interest In Taking Over Intel Wanes Due To 'Complexities' Involved: Report

UBS analyst Thomas Wadewitz assumes Alaska Air Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) with a Buy rating and announces Price Target of $72.

UBS Assumes Alaska Air Gr at Buy, Announces Price Target of $72

Guidance

BURL

Burlington Stores Expects Q4 Total Sales To Increase 5% To 7%; Comparable Store Sales To Increase 0% To 2%; Adjusted EPS Of $3.55 - $3.75 (Est $3.77)

MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) reported quarterly losses of $(0.98) per share which missed the analyst consensus estimate of $(0.45) by 117.78 percent. The company reported quarterly sales of $4.36 million which missed the analyst consensus estimate of $6.01 million by 27.49 percent. This is a 8.81 percent decrease over sales of $4.78 million the same period last year.

MDWD

MediWound Q3 2024 GAAP EPS $(0.98) Misses $(0.45) Estimate, Sales $4.36M Miss $6.01M Estimate

Outlook for the First Quarter of Fiscal Year 2025
For the first quarter of fiscal 2025, we are forecasting revenue of $2.35 billion, +/- $100 million. At the midpoint of this revenue outlook, we expect reported operating margin of approximately 22.0%, +/- 130 bps, and adjusted operating margin of approximately 40.0%, +/- 100 bps. We are planning for reported EPS to be $0.80, +/- $0.10, and adjusted EPS to be $1.53, +/- $0.10.&nbsp;&nbsp;

Analog Devices Sees Q1 Adj. EPS $1.43-$1.63 vs $1.56 Est., Revenue $2.25B-$2.45B vs $2.34B Est.

Matt Bilunas, Best Buy CFO, said "At the same time, we are maintaining our full year non-GAAP operating income rate of 4.1% to 4.2%, which represents slight expansion compared to FY24 on a 52-week basis."
Comparable sales1 of (3.5%) to (2.5%), which compares to prior guidance of (3.0%) to (1.5%).
&nbsp;

Best Buy Cuts FY25 Revenue Outlook From $41.3B - $41.9B To $41.1B - $41.5B, Est $41.592B; Revises Adj EPS Outlook From $6.10 - $6.35 To $6.10 - $6.25 (Est $6.25)

Needham analyst Mayank Tandon reiterates PAR Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAR#NYSE">PAR</a>) with a Buy and announces $90 price target.

Needham Reiterates Buy on PAR Technology, Announces $90 Price Target

Outlook
For fiscal 2025, the Company reiterates its full year revenue guidance of £650 million to £670 million and adjusted EBITDA guidance of £145 million to £160 million. The club remains committed to, and in compliance with, both the Premier League's Profit and Sustainability Rules and UEFA's Financial Fair Play Regulations.

MANU

Manchester United Reiterates 2025 Revenue Guidance Of £650M-£670M And Adjusted EBITDA Guidance Of £145M-£160M

U.S. stocks could open on a sluggish note on Tuesday after ending in green on Monday as President-elect Donald Trump threatened to hit two of U.S.&#8217;s largest trading partners &#8211; Canada and Mexico &#8211; with tariffs.
The Dollar Index strengthened and was hovering around the 107 level. Expectations of a further 25 basis point rate cut in December have fallen to just 59% now, down from 75% a month ago, according <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">to</a> CME Group's FedWatch tool.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.08%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.09%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.07%</td>
</tr>
<tr>
<td>R2K</td>
<td>-0.26%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Monday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was up 0.06% to $597.87 and the Invesco QQQ ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NYSE">QQQ</a>) rose 0.04% to $506.80, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Cues From The Last Session
The Dow Jones closed higher by around 440 points to 44,736.57 on Monday. The S&amp;P 500 rose 0.30% to 5,987.37, while the Nasdaq Composite rose 0.27% to close at 19,054.84 during Monday&#8217;s session.
On the economic data front, the Chicago Fed National Activity Index fell to -0.40 in October compared to -0.27 in the previous month and versus market estimates of -0.20.
The Dallas Fed&#8217;s Texas manufacturing activity index rose to -2.7 in November compared to a reading of -3 in the previous month and versus market estimates of -2.4.
Most sectors on the S&amp;P 500 closed on a positive note, with real estate, materials, and consumer discretionary stocks recording the biggest gains on Monday.
However, energy and information technology stocks bucked the overall market trend, closing the session lower.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.27%</td>
<td>19,054.84</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.30%</td>
<td>5,987.37</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.99%</td>
<td>44,736.57</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1.47%</td>
<td>2,442.03</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
&#8220;Equity markets continue to display remarkable strength. The S&amp;P 500 and other major indices are flirting with or surpassing all-time highs. The breadth of the rally is particularly noteworthy, with a growing number of stocks hitting 52-week highs,&#8221; said Jeremy Siegel, a senior economist <a href="https://resources.wisdomtree.com/weekly-siegel-commentary/">at</a> WisdomTree.
&#8220;This breadth is a key signal of market health, as it indicates a robust and inclusive rally rather than one concentrated in a few mega-cap names,&#8221; he added.
Analysts at BlackRock <a href="https://www.blackrock.com/us/individual/insights/blackrock-investment-institute/weekly-commentary">said</a> that they are positive about the AI theme in the technology sector. &#8220;Valuations for AI beneficiaries are supported as tech companies keep beating high earnings expectations. We think upbeat sentiment can broaden out,&#8221; their note said.
BlackRock also added that they see the AI buildout and adoption creating opportunities across sectors. &#8220;We get selective, moving toward beneficiaries outside the tech sector. Broad-based earnings growth and a quality tilt make us overweight U.S. stocks overall.&#8221;
Predicting how December could look like for the stock markets, Ryan Detrick, chief market strategist at Carson Group, highlighted how markets have performed better than average in December in every election year since 1950.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">No month is more likely to be higher than December in an election year (83.3%). <a href="https://t.co/WrOI59tUiR">pic.twitter.com/WrOI59tUiR</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1861092399449284637?ref_src=twsrc%5Etfw">November 25, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Upcoming Economic Data:
This week&#8217;s economic calendar is not as packed as last week&#8217;s due to Thanksgiving. Here are the key events lined up for Tuesday:
<ul>
<li>The S&amp;P Case-Shiller home price index for 20 cities will be released at 9 a.m. ET.</li>
<li>Data on consumer confidence and new home sales will be released at 10 a.m. ET.</li>
<li>The minutes of the Fed's November FOMC meeting will be released at 2 p.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Woodward Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) is up by almost 11% in premarket trading after Pathstone Holdings LLC boosted its position by 28.6% during the 3rd quarter, as per SEC filing. The company also reported a record revenue of $3 billion in the September quarter, aided by the performance in both aerospace and industrial segments.</li>
<li>Rivian Automotive Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) rose 6% in premarket as it reacted to reports that Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) reached a "conditional" settlement concerning a 2020 lawsuit. The Elon Musk-led company had accused Rivian of poaching Tesla employees to get ahold of its EV trade secrets.</li>
<li>Exact Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) was trading above 5.5% in premarket after the company advanced breast cancer care with the Oncotype DX test and genomic profiling research at the San Antonio Breast Cancer Symposium 2024.</li>
<li>Semtech Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) was up over 19% in premarket hours after the chipmaker reported a strong set of earnings. The company posted revenue of $236.8 million for the quarter with quarterly earnings of $0.26 per share as compared to $0.02 per share a year ago.</li>
<li>Blue Bird Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) was down over 10% in premarket after its fourth-quarter earnings missed analyst estimates. The quarterly earnings of $0.77 per share missed the Zacks Consensus Estimate of $0.78 per share. This compares to the EPS of $0.66 in Q4 of the previous fiscal.</li>
<li>Investors are awaiting earnings results from Best Buy Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>), HP Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>), and Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) today.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures rose in the early New York session, advancing 0.93% to hover around $69.57.
The 10-year Treasury note yield eased to 4.293%.
Major Asian markets ended lower on Tuesday, except for Hong Kong&#8217;s Hang Seng Index. European markets were also down in early trading.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42180029/ark-invest-shakes-up-portfolio-with-big-tesla-and-amazon-trades">Cathie Wood-Led Ark Invest&#8217;s Latest Portfolio Maneuver: Dumps Tesla And Palantir Shares, Buys Amazon And AMD Stock</a></li>
</ul>
Photo courtesy: Wikimedia

Equities

Economics

Federal Reserve

Pre-Market Outlook

Movers

Trading Ideas

DELL

EXAS

RIVN

SMTC

US Stocks May Have A Slow Start As Trump's Tariff Threat Begins To Thwart Relief Rally: Analysts Remain Optimistic About AI-Linked Sectors Stocks

Full Year 2024 Outlook
The Company's Full Year Outlook for 2024 is presented below:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Metric</td>
<td colspan="1" rowspan="1">2024 Outlook</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Earnings per diluted share</td>
<td colspan="1" rowspan="1">
●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; $13.65 to 13.95
•&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on approximately 83 million diluted shares outstanding
•&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on an effective tax rate of approximately 23%
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net sales</td>
<td colspan="1" rowspan="1">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; $13.2 billion to 13.3 billion</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Comparable sales</td>
<td colspan="1" rowspan="1">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Growth of 3.6% to 4.2%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Capital expenditures</td>
<td colspan="1" rowspan="1">
●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Approximately $900 million on a gross basis
●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Approximately $800 million on a net basis
</td>
</tr>
</tbody>
</table>
</figure>

Retail Sales

DICK'S Sporting Goods Expects FY24 EPS Of $13.65-$13.95, Up From $13.55-13.90 Previously Compared To Consensus Of $13.88, With Growth Of 3.6%-4.2%

Press Releases

Millionaires Club Founder and Top 100 Global MLM Earner Edgar Mojica Joins DYNAMAXX as Co-Founder: Full Alliance Group (OTC: "FAGI") Teams Up with Network Marketing Dynamo, Edgar Mojica, who will be Leading DYNAMAXX in its International Expansion, Product Reformulation and Relaunch

Dynamaxx Revitalizes its Product Portfolio, Launches Nine Enhanced and Newly Formulated Offerings: Full Alliance Group (OTC: "FAGI")

Full Alliance Group, Inc. Announces Craig Lane as President of its wholly owned subsidiary DYNAMAXX Health, Inc. (OTC: FAGI)

Full Alliance Group, Inc.'s (OTC:FAGI) Wholly Owned Subsidiary DynaMAXX Health, Inc. Launches PRiVIVE(TM) Topical Serum: A Revolutionary Solution for Cellular Rejuvenation and Dermal Health

Full Alliance Group, Inc. Congratulates Corinne Sanzone and Leslie DuRant of Our Clean Paws, Inc. on Their Feature on Fox & Friends

Full Alliance Group, Inc. (OTC: FAGI) and DynaMAXX Health, Inc. Announce its Grand Opening of the First Ever Cash Pay Anti-Aging and Rejuvenation Direct Sales MAXX Health Clinic, in The Villages, Florida

Full Alliance Group, Inc. (OTC: FAGI) Wholly Owned Subsidiary Dynamaxx Health Inc. Secures Its Own Manufacturing Contract for Medical Devices for MAXX Health Clinics

Comments

Full Alliance Group

Full Alliance Group (FAGI) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga